Class | Agent | FDA pregnancy category | Adverse effects in human pregnancy | Summary risk assessment |
---|---|---|---|---|
Corticosteroids | Prednisone | C | Oral clefts increased risk (two- to three-fold). Intrauterine growth restriction (dose related) | Based on available data, teratogenic risk for corticosteroids is minimal |
 | Cortisone | D |  |  |
 | All others | C |  |  |
NSAIDs | Celecoxib | C | Ibuprofen associated with increased risk (two- to three-fold) for gastroschisis. NSAIDs associated with increased risk for spontaneous abortion; possible increased risk for cardiac defects; premature closure of the ductus arteriosus with third trimester use | Significant risk for premature closure of the ductus arteriosus and other complications when exposure occurs in late pregnancy; minimal or undetermined risk for structural defects following first trimester exposure |
 | Diclofenac | C |  |  |
 | Ketorolac | C |  |  |
 | Prixicam | C |  |  |
 | All others | B |  |  |
 | All NSAIDs in third trimester | D |  |  |